Jeffrey R. Stewart - 16 Feb 2023 Form 4 Insider Report for AbbVie Inc. (ABBV)

Role
EVP, COMMERCIAL OPERATIONS
Signature
Steven L. Scrogham, attorney-in-fact for Jeffrey R. Stewart
Issuer symbol
ABBV
Transactions as of
16 Feb 2023
Net transactions value
$0
Form type
4
Filing time
21 Feb 2023, 17:02:09 UTC
Previous filing
25 Mar 2022
Next filing
02 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABBV Common Stock, $0.01 par value Award $0 +32,085 +53% $0.000000 93,026 16 Feb 2023 Direct F1
transaction ABBV Common Stock, $0.01 par value Award $0 +7,486 +8% $0.000000 100,512 16 Feb 2023 Direct F2
transaction ABBV Common Stock, $0.01 par value Award $0 +8,812 +8.8% $0.000000 109,324 16 Feb 2023 Direct F3
transaction ABBV Common Stock, $0.01 par value Award $0 +7,842 +7.2% $0.000000 117,166 16 Feb 2023 Direct F4
holding ABBV Common Stock, $0.01 par value 1,338 16 Feb 2023 By spouse in trust F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABBV Option (Right to Buy) Award $0 +35,111 $0.000000 35,111 16 Feb 2023 Common Stock 35,111 $149.62 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.
F2 Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.
F3 Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.
F4 Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.
F5 The reporting person disclaims beneficial ownership of all securities held by his spouse.
F6 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 11,704 on February 16, 2024, 11,704 on February 16, 2025, and 11,703 on February 16, 2026.